Multiple high-risk cytogenetic aberrations confer a progressively negative impact on survivals of newly diagnosed myeloma patients

被引：0
|
作者：
Mao, Xuehan [1 ,2 ]
Xu, Yan [3 ]
Yan, Yuting [1 ,2 ]
Liu Jiahui [1 ,2 ]
Fan Huishou [1 ,2 ]
Sui Weiwei [1 ,2 ]
Zengjun, Lizengjun [1 ,2 ]
Deng, Shuhui [4 ,5 ]
Yi, Shuhua [1 ,2 ]
Wang, Tingyu [1 ,2 ]
Wang, Qi [6 ]
Liu, Hui-Min [1 ,2 ]
Qiu, Lugui [1 ,2 ]
An, Gang [1 ,2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union, Inst Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union, Blood Dis Hosp, Tianjin, Peoples R China
[3] Chinese Acad Med Sci, Inst Hematol & Blood Dis, Tianjin, Peoples R China
[4] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
[5] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Medi, Iymphoma & Myeloma, Blood Dis Hosp, Tianjin, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
cytogenetic abnormality; myeloma; survival;
D O I：
10.1016/j.clml.2019.09.132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP-047
引用
收藏
页码：E83 / E83
页数：1
相关论文
共 50 条
  • [1] Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma
    Binder, Moritz
    Rajkumar, S. Vincent
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Hwa, Yi L.
    Zeldenrust, Steven R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Kapoor, Prashant
    Go, Ronald S.
    Gonsalves, Wilson I.
    Kyle, Robert A.
    Kumar, Shaji
    BLOOD, 2016, 128 (22)
  • [2] PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Binder, M.
    Rajkumar, S. V.
    Ketterling, R. P.
    Dispenzieri, A.
    Lacy, M. Q.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Hwa, Y. L.
    Zeldenrust, S. R.
    Lust, J. A.
    Russell, S. J.
    Leung, N.
    Kapoor, P.
    Go, R. S.
    Gonsalves, W. I.
    Kyle, R. A.
    Kumar, S. K.
    HAEMATOLOGICA, 2017, 102 : 107 - 107
  • [3] Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma
    Naimisha Marneni
    Rajshekhar Chakraborty
    Current Hematologic Malignancy Reports, 2021, 16 : 148 - 161
  • [4] Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma
    Marneni, Naimisha
    Chakraborty, Rajshekhar
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (02) : 148 - 161
  • [5] Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome
    Kapoor, Prasnant
    Kumar, Shaji
    Fonseca, Rafael
    Lacy, Martha Q.
    Wilzig, Thomas E.
    Hayman, Suzanne R.
    Dispenzieri, Angela
    Buadi, Francis
    Bergsagel, P. Leif
    Gertz, Morie
    Dalton, Robert
    Mikhael, Joseph
    Dingli, David
    Reeder, Craig B.
    Lust, John A.
    Russell, Stephen
    Roy, Vivek
    Zeldenrust, Steven R.
    Stewart, Keith
    Kyle, Robert A.
    Greipp, Philip R.
    Rajkumar, S. Vincent
    BLOOD, 2008, 112 (11) : 42 - 43
  • [6] Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma
    陈智
    ChinaMedicalAbstracts(InternalMedicine), 2022, 39 (03) : 182 - 183
  • [7] Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
    M Binder
    S V Rajkumar
    R P Ketterling
    P T Greipp
    A Dispenzieri
    M Q Lacy
    M A Gertz
    F K Buadi
    S R Hayman
    Y L Hwa
    S R Zeldenrust
    J A Lust
    S J Russell
    N Leung
    P Kapoor
    R S Go
    W I Gonsalves
    R A Kyle
    S K Kumar
    Blood Cancer Journal, 2017, 7 : e600 - e600
  • [8] Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
    Binder, M.
    Rajkumar, S. V.
    Ketterling, R. P.
    Greipp, P. T.
    Dispenzieri, A.
    Lacy, M. Q.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Hwa, Y. L.
    Zeldenrust, S. R.
    Lust, J. A.
    Russell, S. J.
    Leung, N.
    Kapoor, P.
    Go, R. S.
    Gonsalves, W. I.
    Kyle, R. A.
    Kumar, S. K.
    BLOOD CANCER JOURNAL, 2017, 7 : e600 - e600
  • [9] Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities
    Cavo, Michele
    Bringhen, Sara
    Terragna, Carolina
    Omede, Paola
    Marzocchi, Giulia
    Ruggeri, Marina
    Durante, Sandra
    Petrucci, Maria Teresa
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Montefusco, Vittorio
    Narni, Franco
    Falcone, Antonietta
    Califano, Catello
    Baraldi, Anna
    Pasini, Silvana
    Galieni, Piero
    Morabito, Fortunato
    Grasso, Mariella
    Gottardi, Daniela
    Rizzo, Vincenzo
    Boccadoro, Mario
    Testoni, Nicoletta
    Palumbo, Antonio
    BLOOD, 2010, 116 (21) : 342 - 343
  • [10] Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma
    Mohyuddin, Ghulam Rehman
    Abdallah, Al-Ola
    McClune, Brian
    JAMA ONCOLOGY, 2021, 7 (04) : 635 - 635
12345